Abstract 496P
Background
Fruquintinib (F, a highly selective VEGFR inhibitor) plus sintilimab (S, an anti-PD-1 monoclonal antibody) showed promising antitumor activity in both pre-clinical and clinical studies. Here, we reported the results of advanced NSCLC cohort with PD-L1-positive expression in an open-label, multi-cohort, single-arm phase 2 study to evaluate the safety and efficacy of F+S.
Methods
Eligible advanced NSCLC pts were those who failed, could not tolerate, were not suitable or unwilling to receive standard treatment; were PD-L1 positive (defined as PD-L1 TPS expression ≥1%); and were without EGFR, ALK or ROS1 genetic alteration if non-sq-NSCLC. Enrolled pts received 21-day cycles of F (5 mg, orally QD, 2 weeks on/1 week off) plus S (200 mg IV, Q3W) until disease progression or intolerable toxicity or the maximum duration of treatment with S (24 mo). The primary endpoint was ORR per RECIST 1.1.
Results
As of May 31, 2023, 13 treatment-naïve pts were enrolled and received treatment of F+S. Median age, 69 yrs (range: 36-75); male, 12 (92.3%) pts; sq-NSCLC, 7 (53.8%) pts; adenocarcinoma, 6 (46.2%) pts. Pts with PD-L1 TPS ≥50% and <50% were 6 (46.2%) and 7 (53.8%), respectively. The median follow-up duration was 17.7 (95%CI: 10.4, 18.4) mo. Among 12 pts with at least one post-baseline tumor assessment, the confirmed ORR was 50.0% (95%CI: 21.1%, 78.9%); DCR was 100% (95%CI: 73.5%, 100%); the median DoR, PFS, and OS were all not reached. 15mo-PFS rate was 55.9% (95%CI: 24.0%, 79.0%), and 18mo-OS rate was 60.6% (95%CI: 29.4%, 81.4%). When stratified by PD-L1 level (TPS ≥50% vs <50%), 15mo-PFS rate were 66.7% (95%CI: 19.5%, 90.4%) vs 42.9% (95%CI: 5.8%, 77.7%), 18mo-OS rate were 66.7% (95%CI: 19.5%, 90.4%) vs 53.6% (95%CI: 13.2%, 82.5%). The median treatment duration of F and S were both 8.3 mo (range 0.7-18.6). All pts experienced TEAEs, and the most common (≥10%) ≥G3 treatment related TEAE was only blood pressure increased (15.4%).
Conclusions
F plus S showed a promising antitumor activity and manageable toxicity for advanced NSCLC with PD-L1-positive status. This study might represent a potential treatment option for these pts, especially for pts who can not tolerate chemotherapy.
Clinical trial identification
NCT03903705.
Editorial acknowledgement
Editorial support is provided by Ye Liu from HUTCHMED Limited.
Legal entity responsible for the study
HUTCHMED Limited.
Funding
HUTCHMED Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract